Chemical Information | |
Antiviral agent ID | DrugRepV_6884 | |
Antiviral agent name | 4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide | |
IUPAC Name | 4-[5-(2-methylphenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonamide | |
SMILES (canonical) | [H]N([H])S(=O)(=O)C1=CC=C(C=C1)N1N=C(CC1C1=CC=CC=C1C)C1=CC=C(OC2=CC=CC=C2)C=C1 | |
Molecular Formula | C28H25N3O3S | |
Molecular Weight (g/mol) | 483.59 | |
InChl | InChI=1/C28H25N3O3S/c1-20-7-5-6-10-26(20)28-19-27(30-31(28)22-13-17-25(18-14-22)35(29,32)33)21-11-15-24(16-12-21)34-23-8-3-2-4-9-23/h2-18,28H,19H2,1H3,(H2,29,32,33) | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Human immunodeficiency virus (HIV) 1 NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | BHK-21
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.01 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | 13.0 ± 0.6 μM
| |
Secondary Indication (Cell based assay) | MTT assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | 7 μM | |
Reference | Fioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R..Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation..Eur J Med Chem. 2017 Dec 1;141:15-25. doi: 10.1016/j.ejmech.2017.09.060. Epub 2017 Sep 28. PMID:29028528
| |
Comment | 6-Azauridine, ribavirin, 2'-C-methyl-guanosin (NM108), efavirenz (EFV), pleconaril, acyclovir (ACG), and mycophenolic acid (M5255) were employed as reference inhibitors.
| |